 |
 | Home | Contact Us | FAQ | Search & Site Map | Link to Us |
 | Sign In | Join | Other 45 Sites in Network |
Medical Forum / Diseases and Disorders / Cancer / April 2008Kidney cancer - sutent or IMA 901
Hi J and everyone Sutent works by impeding angiogenesis. An article I read today describes it as a 'targeted' therapy. Does that mean it is designed to only block angiogenisis in cancer cells? I had assumed that angiogenesis was a natural function even in an adult, but does it only occur during development? If that is the case, sutent seems a bit more interesting. The hospital are encouraging me to do a trial of the vaccine IMA 901. This has only been tried on 28 people before (phase 1), and I'd be one of 70 in the phase 2. I feel somewhat that if I do it, it is entirely speculative. I also feel pressured by the last oncologist I saw. But there again, I feel I would like to do a treatment. If there was something out there with a 50% cure rate, I'd jump at it, but there isn't anything even close. Sutent would give me side effects for the rest of my life; ulcers hands feet mouth irritation. 901 might be ineffective 901 is apparantly easy to tolerate with no known side effects. decisions decisions! Tony > Hi J and everyone > Sutent works by impeding angiogenesis. [quoted text clipped - 21 lines] > > Tony Tony, I don't know about sutent, but I had Avastin, which is also an angiogenesis inhibitor. It doesn't just act on cancer cells, but for an adult the other major need of new blood supply is in tissue repair. My docs had me wait something like 6 weeks after surgery before getting Avastin, so my body would have time to repair the surgery damage. Since then, no serious side-effects, and no expectation of long-term problems (unlike, say, Oxaliplatin). Angiogenesis inhibitors are a fascinating chapter in cancer treatment. We found a video about the history of this group of drugs, but I don't recall the name---you may find something good in your local library. Of course, your oncologist should always be your first and last source of information about your treatment. Good luck, whatever your decision. --- CSM > Hi J and everyone > Sutent works by impeding angiogenesis. [quoted text clipped - 21 lines] > > Tony Hello Tony, Here's the 901 one http://www.cancerhelp.org.uk/trials/trials/selectsearch.asp Trial 5 A trial looking at IMA901 vaccine and GM-CSF, with or without cyclophosphamide for advanced kidney cancer This trial is looking at a new vaccine treatment called IMA901 and the growth factor GM-CSF with or without one dose of cyclophosphamide for advanced kidney cancer. Renal cell cancer is the most common type of kidney cancer. If it spreads to somewhere else in the body it can be difficult to treat. Doctors are always looking for new treatments, or new combinations of treatment that may work better. IMA901 is a new vaccine treatment that is a type of immunotherapy. This means it uses the immune system to kill cancer cells. IMA901 is an experimental treatment and researchers are not sure yet how well it will work. In this trial, people will have IMA901 with GM-CSF (Leukine). This is a growth factor that is sometimes used after chemotherapy to increase the number of white blood cells in the body. Doctors think that giving GM-CSF shortly before IMA901 will help the vaccine to work better. Doctors also think that one dose of cyclophosphamide may help IMA901 to work better. But they are not sure yet. In this trial, everyone will have IMA901 and GM-CSF. And some people will also have a single dose of cyclophosphamide before the first IMA901 and GM-CSF injections. The aims of this trial are to find out * If IMA901 can stop your cancer growing or even make it smaller * If cyclophosphamide helps IMA901 to work better * More about the side effects of IMA901 More information about trial 5 * -------------------------------------------------------------------- The latest I have seen about Sutent is some heart problems. So wikipedia is up to speed with me (& vice versa) http://en.wikipedia.org/wiki/Sunitinib Looks like, in Phase III Sutent Progression-free survival (primary endpoint) was more than doubled over Interferon. There's a patient's blog at the bottom. It's not clickable (for me) so I'll post it here http://mpablog.typepad.com/david_foster/2007/09/index.html Interesting, likeable guy. I hope this helps in your decision making. Good to hear from you, Tony. J |
Reply to this Message |
 Sign In
 Join
 My Latest Posts My Monitored Threads My Blog My Photo Gallery My Profile My Homepage Start New Thread Enable EMail Alerts Rate this Thread
|
©2008 Advenet LLC Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.